文献速递乳腺癌

依维莫司联合依西美坦对比单药治疗ER阳性HER2阴性晚期乳腺癌:BOLERO-6随机临床试验

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2018-01-01

BOLERO-6是一项开放标签随机2期试验,纳入309例非甾体芳香化酶抑制剂治疗进展后的绝经后ER阳性HER2阴性晚期乳腺癌患者,随机接受依维莫司联合依西美坦、依维莫司单药或卡培他滨单药治疗。主要目的为估计联合组对比依维莫司单药的PFS风险比,结果为0.74(90%CI 0.57-0.97),支持联合治疗在此人群中的持续使用。

要点

  • 依维莫司联合依西美坦对比依维莫司单药的PFS HR为0.74(90%CI 0.57-0.97)。
  • 联合组对比卡培他滨单药的PFS HR为1.26(90%CI 0.96-1.66),需谨慎解读。
  • 卡培他滨3-4级不良事件发生率74%,联合组70%,依维莫司单药组59%。

核心结论

  • 依维莫司联合依西美坦对比依维莫司单药显示PFS获益,支持该联合方案在此类患者中的持续使用。
  • 卡培他滨对比依维莫司联合依西美坦的PFS数值差异因基线特征不平衡和潜在信息性删失需谨慎解读。

研究设计与样本

  • 开放标签、随机、2期试验,纳入309例在非甾体芳香化酶抑制剂治疗期间进展的绝经后晚期乳腺癌患者,中位年龄61岁(范围32-88岁)。
  • 患者随机分配至依维莫司10 mg/d联合依西美坦25 mg/d组(104例)、依维莫司单药10 mg/d组(103例)或卡培他滨单药1250 mg/m2每日两次组(102例)。
  • 主要终点为依维莫司联合依西美坦对比依维莫司单药的PFS风险比估计,关键次要终点为对比卡培他滨单药的PFS风险比,安全性为次要终点,未计划正式统计比较。

主要发现

  • 从随机化至分析截止(2017年6月1日)的中位随访时间为37.6个月。
  • 依维莫司联合依西美坦对比依维莫司单药的PFS HR估计为0.74(90%CI 0.57-0.97)。
  • 依维莫司联合依西美坦对比卡培他滨单药的PFS HR估计为1.26(90%CI 0.96-1.66)。
  • 分层多变量Cox回归模型中,联合组对比依维莫司单药的HR为0.73(90%CI 0.56-0.97),对比卡培他滨的HR为1.15(90%CI 0.86-1.52)。
  • 3-4级不良事件在卡培他滨组更常见(74%,n=75),联合组为70%(n=73),依维莫司单药组为59%(n=61);严重不良事件在联合组更常见(36%,n=37),依维莫司单药组为29%(n=30),卡培他滨组为29%(n=30)。

关键数值与推荐

  • 依维莫司联合依西美坦对比依维莫司单药的PFS HR为0.74(90%CI 0.57-0.97)。
  • 依维莫司联合依西美坦对比卡培他滨单药的PFS HR为1.26(90%CI 0.96-1.66)。
  • 分层多变量Cox回归模型中,联合组对比依维莫司单药的HR为0.73(90%CI 0.56-0.97),对比卡培他滨的HR为1.15(90%CI 0.86-1.52)。

临床怎么用

  • 对于非甾体芳香化酶抑制剂治疗进展后的绝经后ER阳性HER2阴性晚期乳腺癌患者,依维莫司联合依西美坦可作为二线治疗选择,对比依维莫司单药有PFS获益。
  • 选择卡培他滨或依维莫司联合依西美坦时,应综合考虑基线特征不平衡和潜在信息性删失对PFS比较的影响。
  • 需关注联合组的严重不良事件(36%)和卡培他滨组的3-4级不良事件(74%)。

局限性

  • 开放标签设计可能引入偏倚。
  • 未计划正式统计比较。
  • 存在基线特征不平衡和潜在信息性删失。
  • 样本量有限(共309例),随访至分析截止为37.6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Everolimus plus exemestane and capecitabine are approved second-line therapies for advanced breast cancer. OBJECTIVE: A postapproval commitment to health authorities to estimate the clinical benefit of everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. DESIGN: Open-label, randomized, phase 2 trial of treatment effects in postmenopausal women with advanced breast cancer that had progressed during treatment with nonsteroidal aromatase inhibitors. INTERVENTIONS: Patients were randomized to 3 treatment regimens: (1) everolimus (10 mg/d) plus exemestane (25 mg/d); (2) everolimus alone (10 mg/d); and (3) capecitabine alone (1250 mg/m2 twice daily). MAIN OUTCOMES AND MEASURES: Estimated hazard ratios (HRs) of progression-free survival (PFS) for everolimus plus exemestane vs everolimus alone (primary objective) or capecitabine alone (key secondary objective). Safety was a secondary objective. No formal statistical comparisons were planned. RESULTS: A total of 309 postmenopausal women were enrolled, median age, 61 years (range, 32-88 years). Of these, 104 received everolimus plus exemestane; 103, everolimus alone; and 102, capecitabine alone. Median follow-up from randomization to the analysis cutoff (June 1, 2017) was 37.6 months. Estimated HR of PFS was 0.74 (90% CI, 0.57-0.97) for the primary objective of everolimus plus exemestane vs everolimus alone and 1.26 (90% CI, 0.96-1.66) for everolimus plus exemestane vs capecitabine alone. Between treatment arms, potential informative censoring was noted, and a stratified multivariate Cox regression model was used to account for imbalances in baseline characteristics; a consistent HR was observed for everolimus plus exemestane vs everolimus (0.73; 90% CI, 0.56-0.97), but the HR was closer to 1 for everolimus plus exemestane vs capecitabine (1.15; 90% CI, 0.86-1.52). Grade 3 to 4 adverse events were more frequent with capecitabine (74%; n = 75) vs everolimus plus exemestane (70%; n = 73) or everolimus alone (59%; n = 61). Serious adverse events were more frequent with everolimus plus exemestane (36%; n = 37) vs everolimus alone (29%; n = 30) or capecitabine (29%; n = 30). CONCLUSIONS AND RELEVANCE: These findings suggest that everolimus plus exemestane combination therapy offers a PFS benefit vs everolimus alone, and they support continued use of this therapy in this setting. A numerical PFS difference with capecitabine vs everolimus plus exemestane should be interpreted cautiously owing to imbalances among baseline characteristics and potential informative censoring. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01783444.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Jerusalem G, de Boer RH, Hurvitz S, et al. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29862411. doi:10.1001/jamaoncol.2018.2262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。